Subtype
Esophageal Neuroendocrine Neoplasm
CI-CAN-00000853Explore in graph →
Non-malignant3 active trials
- NCIt
- C5821
Loading cancer entity…
Subtype
CI-CAN-00000853Explore in graph →
Clinical trials
5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05173246 | JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06478264 | A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma | not yet recruiting | Phase 2 | 40 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 27, 2024 | clinicaltrials |
| NCT03811379 | Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials
| unknown |
| Phase 2 |
| 43 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Jan 23, 2019 |
| clinicaltrials |
| NCT02409849 | Octreotide LAR as Maintenance Treatment for Patients With NEC | unknown | Phase 2 | 92 | Peking UniversityOTHER | 1 | Apr 7, 2015 | clinicaltrials |